<p>隨着美國市場連續第四個交易日上漲，受益於超出預期的 GDP 數據和強勁的科技行業表現，投資者越來越關注內部持股比例較高的成長型公司。在這種背景下，內部投資比例高的股票尤其吸引人，因為它們通常表明對公司未來前景的信心，尤其是在不斷變化的經濟環境中。</p>
<h3>美國內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>74%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.1%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.5%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們關於內部持股比例高的快速成長美國公司的 208 只股票的完整列表。</p>
<p>以下是篩選器中一些選擇的簡要介紹。</p>
<h2>ImmunityBio (IBRX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> ImmunityBio, Inc. 是一家商業階段的生物技術公司，專注於開發下一代療法，以增強自然免疫系統對抗癌症和傳染病，市值為 20.5 億美元。</p>
<p><strong>運營：</strong> 該公司通過專注於開發增強免疫系統以對抗癌症和傳染病的先進療法，產生了 8256 萬美元的收入。</p>
<p><strong>內部持股比例：</strong> 30%</p>
<p>ImmunityBio 擁有顯著的內部持股，是一家專注於生物技術領域的成長型公司。最近的公告強調了 ANKTIVA® 在膀胱癌治療中的潛力，得到了有希望的臨牀數據和歐洲監管進展的支持。該公司報告稱 2025 年第三季度收入大幅增長至 3206 萬美元，但面臨負股本和現金流有限的挑戰。儘管過去股東稀釋，ImmunityBio 預計年收入增長 58.5%，高於市場平均水平，目標是在三年內實現盈利。</p>
<ul>
<li>點擊這裏瞭解 ImmunityBio 的細節，查看我們的詳細分析未來增長報告。</li>
<li>我們的綜合估值報告提出了 ImmunityBio 的股價可能低於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月 IBRX 的持股結構</p>
<h2>Uxin (UXIN)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Uxin Limited 是一家在中華人民共和國運營的二手車零售商，市值約為 7.03 億美元。</p>
<p><strong>運營：</strong> Uxin 的收入主要來自其在中國作為二手車零售商的運營。</p>
<p><strong>內部持股比例：</strong> 37.3%</p>
<p>Uxin 擁有大量內部持股，正在擴展其在中國的二手車超級商店網絡。最近在濟南的開業和與天津和銀川等新地點的戰略合作伙伴關係突顯了其增長戰略。該公司預計 2025 年收入將超過 32 億元人民幣，反映出強勁的市場定位。Uxin 的收入預計將以每年 35.5% 的速度增長，超過美國市場平均增長率 10.7%。然而，該股票最近經歷了高波動性。</p>
<ul>
<li>點擊這裏閲讀我們的分析師估計報告，深入瞭解 Uxin 的表現。</li>
<li>我們的估值報告揭示了 Uxin 的股票可能以溢價交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d97cef4a-c4c1-4304-9530-9f3d25d77741/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d97cef4a-c4c1-4304-9530-9f3d25d77741/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月 UXIN 的盈利和收入增長</p>
<h2>RH (RH)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> RH 及其子公司作為零售商和生活方式品牌，在美國、加拿大、英國、德國、比利時和西班牙的家居用品市場運營，市值約為 32.1 億美元。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其 Restoration Hardware (RH) 部門，產生 32.1 億美元，以及其 Waterworks 部門，貢獻 2 億 002 萬美元。</p>
<p><strong>內部持股比例：</strong> 16.7%</p>
<p>RH 顯示出強勁的內部持股，管理層利益與股東一致。該公司報告稱 2025 年第三季度盈利和收入均有所增加，淨收入上升至 3627 萬美元。儘管收入增長落後於更廣泛的市場，RH 的盈利預計在未來三年將顯著增長，年均增長率為 33.1%，超過美國市場平均水平。最近在底特律和曼哈塞特的擴張突顯了其對沉浸式零售體驗的承諾，可能增強長期增長前景。</p>
<ul>
<li>點擊這裏探索我們在 RH 盈利增長報告中的詳細發現。</li>
<li>我們的綜合估值報告提出了 RH 的股價可能高於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef6eec6a-cd7d-42a3-9b5b-224db638a3e7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef6eec6a-cd7d-42a3-9b5b-224db638a3e7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月 RH 的盈利和收入增長</p>
<h2>關鍵要點</h2>
<ul>
<li>點擊這裏解鎖我們關於 208 家內部持股比例高的快速成長美國公司的綜合列表。</li>
<li>尋找替代機會？發現下一個大機會，投資於財務穩健的低價股，平衡風險與回報。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<p>國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

優信

IBRX

<p>這篇文章強調了具有顯著內部持股的成長型公司，表明對其未來前景的信心。值得注意的公司包括 ImmunityBio、Uxin 和 RH，它們都表現出強勁的內部持股和良好的增長預測。ImmunityBio 專注於生物技術療法，Uxin 在中國擴展其二手車網絡，而 RH 則提升零售體驗。分析表明，這些公司可能在財務上被低估或高估，為尋求增長機會的投資者提供了洞察</p>

<p>As the U.S. market experiences a fourth consecutive session of gains, buoyed by better-than-expected GDP data and a strong tech sector performance, investors are increasingly focusing on growth companies with significant insider ownership. In this context, stocks with high levels of insider investment can be particularly appealing as they often indicate confidence in the company's future prospects amidst an evolving economic landscape.</p>
<div class="lb-trans"><p>隨着美國市場連續第四個交易日上漲，受益於超出預期的 GDP 數據和強勁的科技行業表現，投資者越來越關注內部持股比例較高的成長型公司。在這種背景下，內部投資比例高的股票尤其吸引人，因為它們通常表明對公司未來前景的信心，尤其是在不斷變化的經濟環境中。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>74%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.1%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.5%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>74%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.1%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.5%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 208 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們關於內部持股比例高的快速成長美國公司的 208 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的簡要介紹。</p>
</div><h2>ImmunityBio (IBRX)</h2>
<div class="lb-trans"><h2>ImmunityBio (IBRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ImmunityBio, Inc. is a commercial-stage biotechnology company focused on developing next-generation therapies to enhance the natural immune system against cancers and infectious diseases, with a market cap of $2.05 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ImmunityBio, Inc. 是一家商業階段的生物技術公司，專注於開發下一代療法，以增強自然免疫系統對抗癌症和傳染病，市值為 20.5 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $82.56 million from its focus on developing advanced therapies that enhance the immune system to combat cancers and infectious diseases.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過專注於開發增強免疫系統以對抗癌症和傳染病的先進療法，產生了 8256 萬美元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 30%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 30%</p>
</div><p>ImmunityBio, with significant insider ownership, is a growth-focused company in the biotech sector. Recent announcements highlight the potential of ANKTIVA® for bladder cancer treatment, supported by promising clinical data and European regulatory progress. The company reported substantial revenue growth to US$32.06 million in Q3 2025 but faces challenges with negative equity and limited cash runway. Despite past shareholder dilution, ImmunityBio's projected revenue growth of 58.5% annually positions it above market averages, aiming for profitability within three years.</p>
<div class="lb-trans"><p>ImmunityBio 擁有顯著的內部持股，是一家專注於生物技術領域的成長型公司。最近的公告強調了 ANKTIVA® 在膀胱癌治療中的潛力，得到了有希望的臨牀數據和歐洲監管進展的支持。該公司報告稱 2025 年第三季度收入大幅增長至 3206 萬美元，但面臨負股本和現金流有限的挑戰。儘管過去股東稀釋，ImmunityBio 預計年收入增長 58.5%，高於市場平均水平，目標是在三年內實現盈利。</p>
</div><ul>
<li>Click here to discover the nuances of ImmunityBio with our detailed analytical future growth report.</li>
<li>Our comprehensive valuation report raises the possibility that ImmunityBio is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 ImmunityBio 的細節，查看我們的詳細分析未來增長報告。</li>
<li>我們的綜合估值報告提出了 ImmunityBio 的股價可能低於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/ownership-breakdown"/></p>
<p>IBRX Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 IBRX 的持股結構</p>
</div><h2>Uxin (UXIN)</h2>
<div class="lb-trans"><h2>Uxin (UXIN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Uxin Limited is a used car retailer operating in the People's Republic of China with a market cap of approximately $703.04 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Uxin Limited 是一家在中華人民共和國運營的二手車零售商，市值約為 7.03 億美元。</p>
</div><p><strong>Operations:</strong> Uxin's revenue is primarily generated from its operations as a used car retailer in China.</p>
<div class="lb-trans"><p><strong>運營：</strong> Uxin 的收入主要來自其在中國作為二手車零售商的運營。</p>
</div><p><strong>Insider Ownership:</strong> 37.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 37.3%</p>
</div><p>Uxin, with substantial insider ownership, is expanding its used car superstore network in China. Recent openings in Jinan and strategic partnerships for new locations like Tianjin and Yinchuan underscore its growth strategy. The company expects 2025 revenues to exceed RMB 3.2 billion, reflecting strong market positioning. Uxin's revenue is forecast to grow at 35.5% annually, surpassing the US market average growth rate of 10.7%. However, the stock has experienced high volatility recently.</p>
<div class="lb-trans"><p>Uxin 擁有大量內部持股，正在擴展其在中國的二手車超級商店網絡。最近在濟南的開業和與天津和銀川等新地點的戰略合作伙伴關係突顯了其增長戰略。該公司預計 2025 年收入將超過 32 億元人民幣，反映出強勁的市場定位。Uxin 的收入預計將以每年 35.5% 的速度增長，超過美國市場平均增長率 10.7%。然而，該股票最近經歷了高波動性。</p>
</div><ul>
<li>Get an in-depth perspective on Uxin's performance by reading our analyst estimates report here.</li>
<li>Our valuation report unveils the possibility Uxin's shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏閲讀我們的分析師估計報告，深入瞭解 Uxin 的表現。</li>
<li>我們的估值報告揭示了 Uxin 的股票可能以溢價交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d97cef4a-c4c1-4304-9530-9f3d25d77741/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d97cef4a-c4c1-4304-9530-9f3d25d77741/chart/earnings-and-revenue-growth"/></p>
<p>UXIN Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 UXIN 的盈利和收入增長</p>
</div><h2>RH (RH)</h2>
<div class="lb-trans"><h2>RH (RH)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> RH, along with its subsidiaries, operates as a retailer and lifestyle brand in the home furnishings market across the United States, Canada, the United Kingdom, Germany, Belgium, and Spain with a market cap of approximately $3.21 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> RH 及其子公司作為零售商和生活方式品牌，在美國、加拿大、英國、德國、比利時和西班牙的家居用品市場運營，市值約為 32.1 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Restoration Hardware (RH) segment, generating $3.21 billion, and its Waterworks segment, contributing $200.02 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其 Restoration Hardware (RH) 部門，產生 32.1 億美元，以及其 Waterworks 部門，貢獻 2 億 002 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 16.7%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 16.7%</p>
</div><p>RH demonstrates strong insider ownership, aligning management interests with shareholders. The company reported increased earnings and revenue for Q3 2025, with net income rising to US$36.27 million. Despite revenue growth lagging behind the broader market, RH's earnings are forecast to grow significantly at 33.1% annually over the next three years, outpacing the US market average. Recent expansions in Detroit and Manhasset highlight its commitment to immersive retail experiences, potentially enhancing long-term growth prospects.</p>
<div class="lb-trans"><p>RH 顯示出強勁的內部持股，管理層利益與股東一致。該公司報告稱 2025 年第三季度盈利和收入均有所增加，淨收入上升至 3627 萬美元。儘管收入增長落後於更廣泛的市場，RH 的盈利預計在未來三年將顯著增長，年均增長率為 33.1%，超過美國市場平均水平。最近在底特律和曼哈塞特的擴張突顯了其對沉浸式零售體驗的承諾，可能增強長期增長前景。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in RH's earnings growth report.</li>
<li>Our comprehensive valuation report raises the possibility that RH is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏探索我們在 RH 盈利增長報告中的詳細發現。</li>
<li>我們的綜合估值報告提出了 RH 的股價可能高於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef6eec6a-cd7d-42a3-9b5b-224db638a3e7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ef6eec6a-cd7d-42a3-9b5b-224db638a3e7/chart/earnings-and-revenue-growth"/></p>
<p>RH Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 RH 的盈利和收入增長</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Unlock our comprehensive list of 208 Fast Growing US Companies With High Insider Ownership by clicking here.</li>
<li>Looking For Alternative Opportunities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們關於 208 家內部持股比例高的快速成長美國公司的綜合列表。</li>
<li>尋找替代機會？發現下一個大機會，投資於財務穩健的低價股，平衡風險與回報。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

三家內部持股比例高達 37% 的成長型公司